LU, YEN-TA,吕衍达,呂衍達,HUANG, PING-YEN,黄品谚,黃品諺,CHANG, CHIA-MING,张家鸣,張家鳴,TSAI, I-FANG,蔡宜芳,LEE, FRANK WEN-CHI,李 文机,李 文機,CHANG, HUEI-LING,张惠玲,張惠玲
申请号：
TW108128378
公开号：
TW202019469A
申请日:
2019.08.08
申请国别(地区):
TW
年份:
2020
代理人:
摘要：
A pharmaceutical composition for use in treating hepatitis B virus (HBV) infection includes an effective amount of an antibody against CD11b or a binding fragment thereof. A method for treating hepatitis B virus infection includes administering to a subject in need thereof an antibody against CD11b. Anti-CD11b antibody binding to CD11b may trigger immunostimulatory responses, as evidenced by the following observations: increased surface expression of MHC II and CD86 in CD11b+ peripheral blood mononuclear cells (PBMCs)； suppressed level of hepatitis B surface antigen (HBsAg) and HBV DNA in the blood； and accelerated clearance of HBV from liver.一種用於治療B型肝炎病毒(HBV)感染之醫藥組合物包括有效量之對抗CD11b之抗體或其結合片段。一種用於治療B型肝炎病毒感染之方法包括向有需要之個體投與對抗CD11b之抗體。與CD11b結合之抗CD11b抗體可觸發如藉由以下觀測結果所證明之免疫刺激性反應：CD11b+外周血液單核細胞(PBMC)中MHC II及CD86之表面表現增加；血液中B型肝炎表面抗原(HBsAg)及HBV DNA之含量受到抑制；及HBV自肝臟之清除加速。
